Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. Azijn H, et al. Among authors: van craenenbroeck e. Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23. Antimicrob Agents Chemother. 2010. PMID: 19933797 Free PMC article.
Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations.
Van der Borght K, Van Craenenbroeck E, Lecocq P, Van Houtte M, Van Kerckhove B, Bacheler L, Verbeke G, van Vlijmen H. Van der Borght K, et al. Among authors: van craenenbroeck e, van houtte m, van kerckhove b, van vlijmen h. BMC Bioinformatics. 2011 Oct 3;12:386. doi: 10.1186/1471-2105-12-386. BMC Bioinformatics. 2011. PMID: 21966893 Free PMC article.
Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.
Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A, Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, Perez-Elias M, Castor D, Hammer S, Rinehart A, Vermeiren H, Van Craenenbroeck E, Bacheler L. Winters B, et al. Among authors: van leth f, van craenenbroeck e. J Acquir Immune Defic Syndr. 2008 May 1;48(1):26-34. doi: 10.1097/QAI.0b013e31816d9bf4. J Acquir Immune Defic Syndr. 2008. PMID: 18360290
A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences.
Steegen K, Bronze M, Van Craenenbroeck E, Winters B, Van der Borght K, Wallis CL, Stevens W, Rinke de Wit TF, Stuyver LJ; ART-A consortium. Steegen K, et al. Among authors: van craenenbroeck e, van der borght k. AIDS Res Ther. 2010 Oct 15;7:38. doi: 10.1186/1742-6405-7-38. AIDS Res Ther. 2010. PMID: 20950432 Free PMC article.
Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype.
Altmann A, Sing T, Vermeiren H, Winters B, Van Craenenbroeck E, Van der Borght K, Rhee SY, Shafer RW, Schülter E, Kaiser R, Peres Y, Sönnerborg A, Fessel WJ, Incardona F, Zazzi M, Bacheler L, Van Vlijmen H, Lengauer T. Altmann A, et al. Among authors: van craenenbroeck e, van vlijmen h, van der borght k. Antivir Ther. 2009;14(2):273-83. Antivir Ther. 2009. PMID: 19430102
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review.
Boen HM, Cherubin M, Franssen C, Gevaert AB, Witvrouwen I, Bosman M, Guns PJ, Heidbuchel H, Loeys B, Alaerts M, Van Craenenbroeck EM. Boen HM, et al. Among authors: van craenenbroeck em. JACC CardioOncol. 2024 Feb 27;6(2):183-199. doi: 10.1016/j.jaccao.2023.12.009. eCollection 2024 Apr. JACC CardioOncol. 2024. PMID: 38774014 Free PMC article. Review.
167 results